Loading
Inflammasome and Immune Disorders · Journal article
Bangladesh Journal of Infectious Diseases · September 8, 2026
Raises a question worth testing. It does not answer one.
This is an early-phase mechanistic study combining dendrosome nanocurcumin and LL-37 peptide in colorectal cancer cell lines and a mouse xenograft model. The work demonstrates altered gene expression (increased Bax, caspase 3, P21; decreased Bcl2) and claims improved survival in treated mice, but lacks rigorous statistical reporting, human relevance, and pre-clinical validation standards needed to advance toward clinical investigation.
In vitro cell line study and in vivo mouse xenograft model. Female BALB/c mice; in vitro: SW742 colorectal cancer tumor cells and IEC-6 normal intestinal epithelial cells.. Intervention: Dendrosome nanocurcumin (DNC) plus LL-37 antimicrobial peptide (50μM each).. Compared with: Control, curcumin alone, and DNC alone.. n = 60. Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran (conducted January 2023 to October 2024)..
Combination of DNC plus LL-37 caused significant decrease in Bcl2 gene expression and increase in Bax, caspase 3, and P21 genes in SW742 CRC cells DNC and curcumin groups showed altered gene expression compared to control Combination treatment improved mouse survival (specific percentage not reported)
Lack of selectivity data: toxicity to normal cells (IEC-6) measured by MTT assay but results not detailed
This preclinical finding is not actionable for clinical practice. Further mechanistic validation, toxicology assessment, pharmacokinetic characterization, and controlled efficacy studies in larger animal models would be required before any consideration of human translation.
Early-phase in vitro and in vivo mechanistic study in animal models with surrogate endpoints (gene expression and apoptosis markers); lacks human data, clinical outcomes, and adequate statistical reporting to support clinical translation.
As stated by the source record.
Quoted from the source exactly as published.
This preclinical finding is not actionable for clinical practice. Further mechanistic validation, toxicology assessment, pharmacokinetic characterization, and controlled efficacy studies in larger animal models would be required before any consideration of human translation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: This study aimed to assess the effect of dendrosome nanocurcumin (DNC) plus LL-37 peptide against CRC cells in vitro and in vivo. Objective: This study aimed to assess the effect of dendrosome nanocurcumin (DNC) plus LL-37 peptide against CRC cells in vitro and in vivo. Methodology: This interventional in vitro and in vivo study was performed in Kufa, Najaf, Iraq from January 2023 to October 2024. This study was conducted in the Noncommunicable Diseases Research Center, Fasa University of Medical Sciences, Fasa, Iran. Sixty female BALB/c mice were purchased. They were divided into control, curcumin, DNC, and a combination of DNC and LL-37 peptide (50μM for each). The cytotoxicity on the SW742 CRC tumor and IEC‐6 normal cell lines was measured using MTT assay. The expression of IL-6, Bax, Bcl2, caspase 3, and P21 genes was measured using RT-qPCR. Results: Gene expression was altered in DNC and curcumin groups compared to the control. The combination of curcumin plus DNC plus LL37 caused a significant decrease in the Bcl2 gene and an increase in the Bax, caspase 3, and P21 genes, respectively. Conclusion: The combination of LL37, curcumin, and DNC caused enhanced apoptosis in SW742 tumor cells and improved mouse survival, which also requires further assessment. Bangladesh Journal of Infectious Diseases, June 2026;13(1):287-292
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.